Virbac generates €768M H1 revenue as currency headwinds trim headline growth to 4.0%
Resolved · earnings · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-07. Check what remains unresolved below before relying on it.
Does the new outlook change what the company is worth?
Euro appreciation against key operating currencies creates a 340bp divergence between Virbac's constant-currency sales (+7.4%) and reported net revenue (+4.0%).
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factVirbac achieved first half 2026 revenue of €768 million. |
| What else was confirmed? | Reported factRevenue increased 7.4% at constant exchange rates and scope (CERS) compared to H1 2025. |
| Does the valuation support acting? | UnknownNo stored valuation assumptions for VBACY yet — this is the next research task. |
| What would change the assessment? | UnknownEUR/USD and EM currency cross impacts on European exporters — Virbac detailed H1 operating margin release and analyst briefing. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Virbac achieved first half 2026 revenue of €768 million.
- · Revenue increased 7.4% at constant exchange rates and scope (CERS) compared to H1 2025.
- · Foreign exchange headwinds reduced reported headline growth to 4.0%.
Public research record
Research framework · page evidenceCompleted event assessment
constant-currency revenue growth offset by foreign exchange translation drag
| Type | Claim | Scope |
|---|---|---|
| Assumption | Virbac achieved first half 2026 revenue of €768 million. | 2026-09-07 |
| Interpretation | constant-currency revenue growth offset by foreign exchange translation drag | VBACY |
Countercase, invalidators, and sources
Moderating FX volatility and steady demand in companion animal therapies drive full-year margin expansion.
- · EUR/USD and EM currency cross impacts on European exporters — Virbac detailed H1 operating margin release and analyst briefing.
- Virbac : Declaration of the number of shares and voting rights 08/2026 · 2026-09-07
What remains unresolved
- Base path
- Organic revenue maintains mid-single-digit momentum with reported metrics reflecting prevailing currency hedging structures.
- Adverse path
- Further deterioration in emerging market currencies intensifies translation headwinds into second-half earnings.
- Supportive path
- Moderating FX volatility and steady demand in companion animal therapies drive full-year margin expansion.
- · EUR/USD and EM currency cross impacts on European exporters — Virbac detailed H1 operating margin release and analyst briefing.this week
Evidence
- Virbac : Declaration of the number of shares and voting rights 08/20262026-09-07
“Virbac announced first half 2026 revenue of €768m, representing 7.4% growth at constant exchange rate and scope (CERS) compared to H1 2025. The growth was driven by double-digit expansion of the Supercharge4 platforms... Currency headwinds impacted actual reported growth to +4.0%.”
Supports: Virbac achieved H1 2026 revenue of €768m, up 7.4% CERS, with currency headwinds moderating reported growth to 4.0%.